DOD Ovarian Cancer Pilot Award | W81XWH 22 OCRP PA

Opportunity Information: Apply for W81XWH 22 OCRP PA

The Department of Defense Ovarian Cancer Research Program (OCRP) Pilot Award is a funding opportunity designed to spark genuinely new ideas in ovarian cancer research, especially early-stage projects that could open up fresh directions for the field. The central goal is to support exploratory, high-impact concepts or theories that have the potential to lead to critical discoveries or major advances, rather than funding work that simply extends what is already known. Projects funded under this mechanism are expected to act as a catalyst that expands or changes current thinking about ovarian cancer biology, prevention, detection, or treatment approaches.

A key requirement is that the proposed work must have a clear and direct focus on ovarian cancer. Applicants are expected to anchor their research in ovarian cancer-relevant resources such as patient tissues, established or novel cell lines, existing datasets, and/or appropriate animal models. If the project relies on particular cell lines or animal models, the application needs to explain why those models are the right choice for the question being asked, rather than treating them as default tools. The program is aiming for strong scientific rationale and fit-for-purpose model selection, since the award is meant to generate results that are meaningful for ovarian cancer specifically.

This Pilot Award is structured to encourage risk-taking and new avenues of investigation, so preliminary data are not required. That said, preliminary data can be included if available, but the absence of prior results should not be a barrier as long as the proposal is well-argued and scientifically sound. Even without preliminary data, the research plan should be built around a well-formulated, testable hypothesis supported by a strong rationale. Importantly, the program makes clear that scientific quality alone is not enough if the work is not innovative; applications that are methodologically solid but do not introduce a novel idea or direction do not match the intent of the Pilot Award.

Innovation is the defining theme of this mechanism. The OCRP frames innovation broadly: projects may introduce a new paradigm, challenge an existing paradigm, reframe a persistent problem from a new angle, or deliver new insights, technologies, or applications that could move the mission forward. In other words, the program is looking for proposals that change the conversation in some way, rather than proposals that mainly confirm, refine, or slightly extend established knowledge.

To clarify what does not fit, the announcement provides examples of projects that are likely to be viewed as insufficiently innovative. These include continuing the next logical step of the applicant's prior work, offering only incremental advancement over already published data, using a standard published set of in vitro assays simply to further characterize an existing model system, or taking known biomarkers and inserting them into in vivo or clinical models without a truly novel conceptual leap. These examples underline that the award is not meant for routine follow-on studies or straightforward validation exercises.

The expected outcome for funded projects is the generation of robust preliminary data that can serve as a foundation for larger future studies and subsequent grant applications. In practice, this means reviewers will likely value proposals that can deliver clear proof-of-concept results, new datasets, prototype methods, or early mechanistic evidence that de-risks a bigger research direction. Finally, it is explicitly stated that clinical trials are not supported under this award mechanism, so projects must remain on the preclinical, translational, or foundational research side rather than interventional clinical testing.

From an administrative standpoint, this opportunity was offered by the Department of Defense, Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA), under Funding Opportunity Number W81XWH-22-OCRP-PA. The funding instruments listed include grants and cooperative agreements, and eligibility is described as unrestricted (open broadly to different entity types), subject to any additional eligibility details in the full announcement. The opportunity was posted March 18, 2022, with an original closing date of August 5, 2022, and anticipated approximately 14 awards. The award ceiling is listed as 0 in the provided data, which typically indicates that applicants need to rely on the full solicitation text for the actual budget limits and constraints.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Ovarian Cancer Pilot Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 18, 2022.
• Applicants must submit their applications by Aug 05, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 14 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 OCRP PA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: